Get started

GLP-1 medicines

Zepbound for sleep apnea: what the approval actually covers

This is the one approval that separates Zepbound from Wegovy, and the one most likely to change what insurance will pay for.

Written from the FDA-approved labelling and the sources listed at the end. Not reviewed by a clinician. · Updated

What the approval says

Zepbound is approved for obstructive sleep apnea in adults with obesity. It is the only GLP-1 medicine that carries this, and it is the clearest difference between Zepbound and Wegovy.

The doses are not the same as for weight alone. The label's maintenance options:

IndicationMaintenance dose
Chronic weight management5 mg, 10 mg or 15 mg weekly
Obstructive sleep apnea10 mg or 15 mg weekly

Everyone still starts at 2.5 mg for four weeks and steps up in 2.5 mg increments with at least four weeks on each dose. The maximum for every indication is 15 mg.

Why this matters more than it sounds

Insurance. A plan that flatly excludes weight-loss medication may still cover a drug prescribed against a diagnosed sleep disorder. Same drug, same person, different answer — because coverage follows the diagnosis, not the molecule. If you have a sleep study showing obstructive sleep apnea, that is worth raising with both your prescriber and your plan before you accept a cash price.

It is a real clinical indication, not a marketing angle. Obstructive sleep apnea in the context of obesity is a serious condition, and this approval exists because the drug was studied against it.

What it does not do

It also does not turn Zepbound into a different drug. The boxed warning about thyroid C-cell tumors applies, as do the contraindications: medullary thyroid carcinoma, MEN 2, serious hypersensitivity. A sleep apnea diagnosis does not create an exception to any of those.

Questions worth asking

  1. Do I have a sleep study confirming obstructive sleep apnea, or a suspicion of it?
  2. Does my plan cover tirzepatide for that diagnosis, even if it excludes weight-loss drugs?
  3. Who is managing the sleep apnea, and do they know I am starting this?
  4. When is the CPAP reassessed?

Where this came from

  1. FDA, Highlights of Prescribing Information: ZEPBOUND (tirzepatide) injection, 2025 revision — accessdata.fda.gov
  2. openFDA drug label API, ZEPBOUND record, retrieved 23 September 2026 — api.fda.gov
Help